Bentz Jeffrey Allen 4
4 · Ault Global Holdings, Inc. · Filed Aug 24, 2021
Insider Transaction Report
Form 4
Bentz Jeff Acosta
Director
Transactions
- Award
Stock Options (Right to Buy)
2021-08-20+150,000→ 150,000 totalExercise: $2.55Exp: 2031-01-07→ Common Stock (150,000 underlying) - Exercise/Conversion
Common Stock
2021-08-20+50,000→ 50,000 total - Exercise/Conversion
Restricted Stock Grant
2021-08-20−50,000→ 50,000 totalFrom: 2021-08-20Exp: 2021-11-15→ Common Stock (50,000 underlying) - Award
Restricted Stock Grant
2021-08-20+50,000→ 50,000 totalExp: 2023-11-15→ Common Stock (50,000 underlying) - Disposition to Issuer
Stock Options (Right to Buy)
2021-08-20−150,000→ 0 totalExercise: $4.49Exp: 2031-01-07→ Common Stock (150,000 underlying)
Footnotes (5)
- [F1]Represents the vesting of restricted stock.
- [F2]Each restricted stock unit is the economic equivalent of one share of Common Stock, par value $0.001, of Ault Global Holdings, Inc.
- [F3]On November 2, 2020, Mr. Bentz was granted 100,000 restricted shares of the Issuer's Common Stock (the "Restricted Shares"), which vest in two equal installments on each of August 20, 2021, and November 15, 2021. The grant of Restricted Shares was approved at the Issuer's Annual Meeting of Stockholders on August 13, 2021, and authorized by the NYSE American on August 20, 2021.
- [F4]On January 8, 2021, Mr. Bentz was granted 50,000 shares of the Issuer's Common Stock (the "Restricted Shares"), which vest in four installments on each of May 15, 2022, November 15, 2022, May 1, 2023 and November 15, 2023. The grant of Restricted Shares was approved at the Issuer's Annual Meeting of Stockholders on August 13, 2021, and authorized by the NYSE American on August 20, 2021.
- [F5]On April 26, 2021, the Issuer's Board of Directors approved an option repricing effective August 20, 2021, which resulted in, for purposes of the Exchange Act, the cancellation of these stock options granted to Mr. Bentz on January 8, 2021, in exchange for new stock options (the "Options") having a lower exercise price of $2.55 per share. All of the other terms of the Options remained unchanged. The Options were approved at the Issuer's Annual Meeting of Stockholders on August 13, 2021, and authorized by the NYSE American on August 20, 2021.